MAM
DNLI icon

Martingale Asset Management’s Denali Therapeutics DNLI Stock Holding History

Martingale Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$477K Sell
18,530
-5
-0% -$103 0.01% 674
2026
Q1 		$356K Hold
18,535
– – 0.01% 707
2025
Q4 		$306K Buy
+18,535
New +$313K 0.01% 696

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's DNLI Position: Q2 2026 in Review

Martingale Asset Management reduced its Denali Therapeutics (DNLI) stake by 0.03% in Q2 2026, selling an estimated $103 and leaving 18,530 shares worth $477K. The position accounts for 0.01% of the portfolio, ranked #674.

Martingale Asset Management first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Martingale Asset Management held 18,530 shares of Denali Therapeutics worth $477K as of Q2 2026.
  • Martingale Asset Management sold 5 Denali Therapeutics shares in Q2 2026, an estimated $103.
  • Denali Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #674 holding.
  • Martingale Asset Management first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.